Tiagabine for Schizophrenia

Phase 3

Waitlist Available

Led By T.-U. Wilson Woo, M.D., Ph.D.

Research Sponsored by Beth Israel Deaconess Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Currently on second-generation antipsychotics for at least 3 months

Age 18-25, otherwise healthy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up symptoms will be assessed at baseline and at 6-month time point to see if symptoms change after 6 months compared to baseline measures

Awards & highlights

Study Summary

This trial will test whether tiagabine can improve brain function in people with early schizophrenia.

Who is the study for?

This trial is for young adults aged 18-25 who have been diagnosed with schizophrenia within the last three years and are on second-generation antipsychotics. It's not for those with schizoaffective disorder, multiple failed antipsychotic trials, neurological disorders, pregnancy, HIV, suicidal tendencies or substance dependence.Check my eligibility

What is being tested?

The study tests if tiagabine can correct brain deficits in early-stage schizophrenia compared to a placebo. Participants will be randomly assigned to receive either tiagabine or an inactive pill without knowing which one they're getting.See study design

What are the potential side effects?

Tiagabine may cause side effects like dizziness, fatigue, nausea, confusion and potentially worsen seizures in people prone to them. The placebo should not cause any direct side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been taking second-generation antipsychotics for over 3 months.

Select...

I am between 18 and 25 years old and generally healthy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ working memory will be assessed at baseline and at 6-month time point to see if working memory changes after 6 months compared to baseline measurement

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~working memory will be assessed at baseline and at 6-month time point to see if working memory changes after 6 months compared to baseline measurement

This trial's timeline: 3 weeks for screening, Varies for treatment, and working memory will be assessed at baseline and at 6-month time point to see if working memory changes after 6 months compared to baseline measurement for reporting.